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Summary 
 
Advanced therapy medicinal products (ATMPs) represent the current pinnacle of “patient-
specific medicines” and will change the nature of medicine in the near future. They fall into 
three categories; somatic cell-therapy products, gene therapy products and cells or tissues 
for regenerative medicine which are termed “tissue engineered” products. The term also 
incorporates “combination products” where a human cell or tissue is combined with a 
medical device. Plainly many of these new medicines share similarities with conventional 
haematological stem cell transplant products and donor lymphocyte infusions as well as 
solid organ grafts and yet ATMPs are regulated as medicines. The development of these 
medicines has remained predominantly in academic settings and within specialist centres. 
However, with the advent of commercialisation of dendritic cell vaccines, CAR-T cells and 
genetically modified autologous haematopoietic stem cells to cure single gene-defects in -
thalassaemia and haemophilia, the widespread availability of these therapies needs to be 
accommodated. 
Uniquely to ATMPs, the patient or an allogeneic donor is regularly part of the manufacturing 
process. All of the examples given above require procurement of blood, bone marrow or an 
apheresate from a patient as a starting material for manufacture. This can only occur in a 
clinical facility licensed for the procurement of human cells for therapeutic use and this is 
likely to fall to haematology departments either as stem cell transplant programmes or as 
blood transfusion departments to provide under a contract with the company which will 
manufacture and supply the final medicine. The resource implications associated with this 
can impact on all haematology departments, not just stem cell transplant units, and should 
not be under-estimated. 
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Introduction 
 
The advent of the EU Medicines Directive in 2001 [2001/83/EC] created a new class of 
medicines which contained or consisted of human cells or tissues and which have been 
termed Advanced Therapy Medicinal Products or “ATMPs”.  ChondroCelect, a mesenchymal 
stromal cell product to repair damaged cartilage led the way in the EU as the first ATMP to 
obtain a manufacturing authorisation for supply as a licensed medicine and was followed by 
Glybera, Provenge and Holoclar. Apart from Glybera, each of these requires procurement of 
patient cells, as a starting material, in a hospital setting which is licensed for therapeutic cell 
procurement. Provenge was the first autologous dendritic cell vaccine to become licensed 
and, although it subsequently failed commercially due to low efficacy, other DC vaccines are 
already in late phase trials. Holoclar, a complex construct of autologous limbal stem cells on 
an engineered scaffold for corneal repair, is the first combination ATMP to obtain an EU 
marketing approval. Late phase, commercial clinical trials of gene-modified autologous 
haematopoietic stem cells for correction of congenital single gene defects, autologous 
monocyte-derived dendritic cell vaccines for a variety of cancers, CAR-T cells and cell-based 
cancer vaccines are all underway, as are early phase trials of complex 3-D regenerative 
medicine constructs by academic groups and commercial developers. 
 
The 2001 Medicines Directive and the Advanced Therapy Medicinal Products regulation 
[Regulation1394/2007] which followed in 2007 introduced the concept of two different 
types of therapeutic cells; “substantially modified” versus “minimally manipulated” or “non-
substantially modified”.  
“Minimally-manipulated” or “non-substantially modified” cells and tissues are not 
medicines but are “cell or tissue therapies” such as conventional haematopoietic stem cell 
transplants and the distinctions will be highlighted below. 
ATMPs are medicines and are divided into three broad classes -  “somatic cells”, “gene 
therapies” and “tissue engineered products” although even this regulatory classification is 
not straightforward an often confusing. Somatic cell medicines can range from allogeneic 
anti-viral T cells to treat post-transplant EBV lymphoma to mesenchymal stromal cells (MSC) 
used for suppression of acute graft versus host disease. Gene-modified CAR-T cells are 
categorised as “gene therapy products” yet their mode of action is not by in vivo genetic 
modification. Moreover, suspensions of autologous or allogeneic MSC used for enhancing 
endogenous repair for cartilage defects are “tissue engineered products” rather than 
“somatic cells” despite the fact that they may have been isolated and manufactured in 
exactly the same process as MSC defined as a “somatic cell therapy” above. Moreover, MSC 
combined with a scaffold for production of an engineered trachea are “combination ATMPs” 
and not “tissue engineered” products!  
These difficulties are compounded further by the similarity between ATMPs and “routine” 
stem cell transplant products where the distinction between “minimally-manipulated” cell 
or tissue therapy, versus an ATMP, is often very challenging and sometimes even 
inconsistent between EU member states. This is compounded by the sheer heterogeneity of 
ATMPs, especially for autologous, or patient-specific allogeneic, products which, following 
the success of CAR-T cells in early trials, is a burgeoning field.  
Taking the UK as an example, the MHRA is the agency with the statutory right to determine 
whether the product is an ATMP or a cell therapy which would then be regulated under the 
EUTCD. This is not a trivial decision since even minimally manipulated therapies might be 
classified as an ATMP if the cells will be used “non-homologously” i.e. not intended to be 
used for the same essential function(s) in the recipient and the donor – even when the cells 
are used autologously. A good example of this regulatory razor are CD133+ bone marrow 
derived progenitor cells isolated by immunomagnetic selection, such as CliniMACS. If these 
cells are used for HSCT then they are unlikely to be classified as “substantially modified” 
since direct cell  separation and concentration without cell culture is “non-substantial 
manipulation” according to the ATMP Regulation 1394. The same cells when injected into a 
coronary artery, or into cardiac muscle to enhance regeneration post myocardial infarct, 
have been classified as an ATMP based on their 'non-homologous' use, i.e. the CD133+ cells 
will be injected into an anatomical site which an EMA expert committee has decided is not a 
physiological site for those cells and thus the risk of the therapy warrants regulation as an 
ATMP.  
[http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000301.jsp&mid
=WC0b01ac05800862c0 ] 
 
The regulation of substantially modified cells in 2001 was rapidly followed by the EU Tissues 
& Cells Directives [2004/23/EC] to regulate non-substantially modified therapies in 2004. 
These include routine HSCT products such as cryopreserved autologous haematopoietic 
stem cells (HSC) and even CD34 selected HSC for allogeneic HSCT since both procedures are 
regarded as minimal manipulation. The EUTCD is the legislation with which all HSCT 
haematologists are familiar since it is the basis of the Human Tissue (Quality and Safety for 
Human Application) Regulations 2007 (Q&S Regulations).Under these Regulations, the 
Human Tissue Authority (HTA) licenses and inspects establishments that undertake the 
procurement, testing, processing, storage and distribution of human cells and tissue for 
therapeutic use and this authority extends to licensing procurement of human cells and 
tissue for manufacture of an ATMP. This piece of legislation requiring licensing of 
procurement of human cells and tissues is unique to the EU. The US Federal Drug 
Administration regulates the manufacture and supply of cell-based medicines and the 
Australian Therapeutic Goods Administration regulates ATMP equivalents as “biological 
medicines” but neither yet requires licensing of the clinical site where the patient or donor 
cells/tissues are procured. 
 
Abbreviations: 
ATMP  Advanced therapy medicinal product 
BE  Blood establishment 
EUTCD  EU Tissues and Cells Directives 
DI  Designated Individual responsible for an HTA licence 
HSC  Haematopoietic stem cell 
HSCT  Haematopoietic stem cell transplant 
HTA  Human Tissue Authority 
JACIE  Joint Accreditation Committee ISCT/EBMT for HSCT programmes 
MHRA  Medicines and Healthcare products Regulatory Agency 
 
 
 
What sorts of cells and tissue might haematology teams need to supply? 
 
In 2013 the UK Department of Health established a Regenerative Medicine Expert Group 
(RMEG) to report on the regulation, logistics and reimbursement of ATMPs in recognition of 
the importance of this new class of medicines. The report [RMEG 2014] concluded that the 
UK NHS Blood & Transplant facilities are well placed to support the procurement of cells and 
tissues as starting materials for ATMP manufacture. Whilst this is true of procurements from 
normal volunteer donors it is unlikely to apply to patient-derived cells and tissues which will 
need to be procured in a hospital setting. 
Given the diversity of ATMPs, the procurements can include surgical biopsies, surgical 
resections, bone marrow aspirates or full harvests, moderate volume blood samples, or 
apheresates from mobilised or non-mobilised patients or donors (table 1). In some cases 
they may be residual cells from a haematopoietic stem cell transplant (HSCT) product such 
as are being used to produce anti-viral T cell products from allogeneic donor HSCT. 
At UCL all three types of ATMP for academic and commercial clinical trials are 
manufactured. The donor-derived cells and tissues used for these products include: small 
volume bone marrow aspirates for mesenchymal stromal cell isolation and seeding of 
decellularised tracheal scaffolds [Elliott et al 2012], surgical biopsies for epithelial cells and 
fibroblasts, muscle biopsies for mesangioblasts for engineered oesophagus products, as well 
as clinical apheresates from autologous and allogeneic donors. In all cases supply 
agreements have been established with third party clinical sites for the procurement of cells 
and tissues under their existing Human Tissue Authority (HTA) procurement licence and 
under the authority of the local HTA Designated Individual (DI). Sometimes these 
agreements are simple and are designed solely to meet the obligations of each party under 
the EU Tissues and Cells Directive (EUTCD). In others, they become complex legal contracts 
taking many weeks to get signed off by the local hospital administration and involving legal 
fees to draft. 
 
For a busy DI in a clinical HSCT unit to take on the paperwork to facilitate non-HSCT 
procurement is challenging; especially for a clinical service which has nothing to do with 
haematology patients. Even setting up the collection of a small bone marrow aspirate for 
the isolation of bone marrow MSC in an out-patient clinic for a regenerative medicine 
product requires new paperwork and often new training records, plus a supply agreement 
with the end user and a process to report any serious adverse events or reactions (SAEARs) 
which may occur after the starting material has left the procurement facility. The complexity 
is increased if procurement activity is extended outside of the HSCT unit, for example to 
cover collection of a tumour resection from an operating theatre by surgeons and theatre 
nurses who have never worked under a regulated quality system.  
Organising the logistics and calculating the costs of procurement and supply to the end user, 
and then invoicing of the end user for the service are all tasks which require resourcing in 
order to provide a service for the supply of starting materials.  
 
Why has this situation arisen? 
 
Whatever the ATMP and whatever the cell or tissue required for its manufacture, the 
procurement is a licensable activity in the EU. In the UK this is regulated mostly by the HTA 
although, in the case of blood cells, the MHRA may regulate under the Blood Establishment 
licensing procedure. Each EU member state has its own regulatory system (www.agora-
gmp.org) and local rules apply. 
Procurement of patient or donor cells and tissues is licensed to ensure appropriate consent 
is obtained, appropriate screening of the donors for infectious disease is performed and full 
traceability of the donor and the donation is in place. Whether the cells/tissues are to be 
used for a routine transplant or as the starting material for manufacture of an ATMP is 
irrelevant from a haematologist’s perspective. The donor or patient cells must be procured 
by an HTA licensed establishment and the donor must be tested for the infectious disease 
markers set out in the HTA Directions. In all licensed establishments the HTA procurement 
licence is overseen by a DI and, in most cases (s)he is within, or associated with, the 
haematology department as part of the HSCT programme. The procurement system to 
support a routine HSCT service is generally established and validated to support the 
procurement of a limited number of types of cell, in a very defined clinical area under the 
control of the DI. However, the procurement licence and the quality system which supports 
it are valuable assets to hospitals facing the challenges of supporting clinical trials and 
routine use of ATMPs; consequently DIs will be faced with requests to supply a range of cells 
and tissues in the near future [Chabannon et al 2014]. Making an existing HSCT 
procurement system work to support the regulated procurement of a wide range of 
different tissues and cells from across the hospital is challenging and potentially expensive. 
 
Is this an opportunity or a risk? 
 
All changes present opportunities and risks and the field of ATMPs presents some of the 
greatest changes to delivery of medicine of the past 20 years. For haematologists involved in 
transfusion or transplantation, these new medicines represent huge opportunities because 
of their established expertise in procurement and traceability of human cells; but the risks 
of providing an academic collaboration or even a commercial service to participate in the 
manufacture of a medicine need to be recognised.  
 
One of the greatest challenges of running an HSCT programme is covering the “back office” 
costs of the apheresis unit and the stem cell processing laboratory; this is why so many HSCT 
programmes have chosen to outsource at least one of these operations to a third party 
provider. Many of these costs are also incurred by blood transfusion departments in 
maintenance of their MHRA licence as Blood Establishments (BE). With the advent of 
academic or commercial supply of procurement services to ATMP companies, there is a 
need to set up a costed service with a billing structure which could be used to support the 
quality manager, DI and the apheresis team with additional resources. This could, in turn, 
subsidise the Blood Transfusion laboratory or HSCT programme to some degree. 
Haematology departments without HSCT programmes may even consider using their 
existing quality systems supporting the blood transfusion services to enable them to obtain 
HTA licensing for procurement and testing of cell and tissues simply to support this 
burgeoning demand or to add procurement to their existing BE licence. 
 
Supply of any service comes with risks, not least the expectation of the purchaser whether 
academic or commercial. The EU Clinical Trials Directive raised the bar for compliance with 
Good Clinical Practice by universities and hospitals involved in academic, early phase trials. 
The provision of cells and tissues to academic colleagues for ATMP manufacture requires a 
contract which is no less complex than one to supply cells to a major pharmaceutical 
company for a clinical trial, and the expectations of the trial office will be the same. 
Scheduling patients referred by other clinical teams for an apheresis slot in a busy HSCT 
practice or arranging a small volume bone marrow aspirate in the Haematology Out-Patient 
Clinic can be challenging; even more so when the end user demands a specific date in order 
to meet a downstream manufacturing deadline. This might require extension of the 
operating hours of the apheresis unit or out-patient clinic, with the additional costs being 
met by the academic or commercial contractor. When providing costs as part of an 
academic grant application these additional costs need to be addressed. 
 
It is essential to establish the product quality characteristics which the end user requires 
before entering into an agreement to supply. ATMPs will never be inexpensive medicines 
and the liability for the final product must remain with the manufacturer. Already there are 
anecdotal reports that some hospitals are seeing this potential liability as a reason not to 
supply starting materials for commercial clinical trials. The supply agreements should 
delineate the specific responsibilities of each party. For example, for starting materials the 
donor screening for infectious disease markers falls under the EUTCD (or EU Blood Directive 
if obtained under this legislation). In the UK this must be carried out by an establishment 
licensed by the HTA or MHRA for donor testing. If the screening misses an early HIV 
infection and the product is manufactured and released who is responsible for the cost of 
the resultant product recall and destruction or, worse, the liability to the patient if it has 
been administered already?  
 
The agreed product characteristics should ensure that the clinical site only provides the end 
user with starting material with sufficient cells of adequate viability and that are free from 
microbial contamination for the downstream manufacturing process. The traceability must 
be guaranteed and records retained for 30 years in accordance with legislative 
requirements. The tests used to show that the starting material meets these pre-
determined standards need to be qualified and, in the case of donor screening and product 
sterility tests, fully validated. It is worth considering outsourcing sterility testing to an MHRA 
licensed testing facility rather than requiring in-house microbiology departments to go 
through formal validation of their sterility assays for your products. Alternatively, the 
supplier can pass the sterility testing of the starting material to the manufacturer of the 
ATMP. If so, then the third party agreement between the HSCT procurement service and the 
ATMP manufacturer must require that the procurement DI is informed of any products 
which are contaminated so that (s)he can report any associated SAEAR to the HTA and 
oversee the route cause analysis or the MHRA if procured as a Blood Establishment. 
 
 
How can a procurement service be established? 
 
As with all changes this will require consultation and a business case for investment (table 
2). Existing HSCT programmes will have set up procurement policies and procedures for 
JACIE compliance and to meet the requirements of the HTA regulation. These may be 
reviewed with hospital legal advisors regarding their suitability for provision of a 
procurement service to third parties, so that standardised templates are created which 
cover regulatory demands and specific requirements of the hospital to define the limits of 
liability. This could substantially reduce the demands on the DI when requests are made. At 
the same time a limited training scheme could be created for staff who need to be included 
within the procurement licence on a short term basis. For example, nurses or junior doctors 
who may be expected to take a bone marrow aspirate for MSC isolation, a surgeon who may 
be required to provide a skin biopsy for the isolation of epithelial cells to make an iPS cell 
line or an obstetrician or midwife who may be asked to provide an umbilical cord or 
placenta. This training can be as simple as a one page summary of the regulations for 
procurement of cells, the importance of donor screening and traceability and the risks of 
contamination of the tissue or cells being procured and how that it minimised by 
appropriate practice. It is the responsibility of the DI to assure that procurement is 
undertaken by suitably trained individuals and a record of all training will need to be 
retained within the site licence for procurement with the staff named on the training record 
held by the DI or the holder of the BE licence if that structure is used. 
 
 
What about reception, storage and dispensing of ATMPs when they arrive from the 
manufacturer? 
 
All medicines received by a hospital become the responsibility of the chief pharmacist and 
conventional medicines are stored within the hospital pharmacy until they are dispensed. 
ATMPs by contrast are often delivered for immediate use with a shelf life measured in hours 
or, more often, arrive cryopreserved in vapour phase nitrogen. Hospital pharmacies do not 
usually have capacity for nitrogen storage. Indeed, even if the planned storage is short term 
within the delivery dry shipper the risk assessments for nitrogen storage and transport of 
the shipper within the hospital could present a problem since pharmacists are unfamiliar 
with the risks of vapour phase nitrogen storage. HSCT programmes already have processes 
and procedures for handling products held in vapour phase nitrogen and for transporting 
them to the wards for infusion. These will have been established and assessed in 
accordance with regulatory (HTA) and (where applicable) JACIE standards. 
Cryopreserved ATMPs are delivered with precise instructions for thawing, together with the 
associated paperwork to record the process. Haematology staff are familiar with thawing 
cryopreserved cell suspensions and with completing paperwork associated with these 
products whereas pharmacists and other healthcare professionals rarely are. 
 
At the Royal Free Hospital the HSCT stem cell laboratory is part of the Centre for Cell, Gene 
& Tissue Therapeutics (CCGTT). Here, a partnership has been established with the Pharmacy 
Department such that all cryopreserved ATMPs are received by the HSCT stem cell 
laboratory staff within the CCGTT rather than through Pharmacy. The products are retained 
within the cryogenic biobank and dispensed to the clinician when requested. The HSCT stem 
cell laboratory staff remain responsible for the transport of the ATMP to the patient and the 
thawing of the product at the patient bedside, irrespective of the clinical team caring for the 
patient. The HSCT laboratory staff then complete the paperwork and provide copies to the 
manufacturer and to Pharmacy. The invoice for the service is raised by the CCGTT staff and 
billed through the Pharmacy business manager. 
 
 
Ethical considerations 
 
The provision of cells and tissues for therapeutic use requires patient/donor consent. The 
process of seeking consent may vary in its complexity depending on a number of factors 
including: the age of the donor; the end use of the tissues and cells and the nature of the 
product being developed; the number of likely recipients; and for ATMPs in particular, the 
stage in the development of the product and the likelihood that it will end up in clinical use.  
Consent forms and information sheets established for an HSCT service are unlikely to be 
sufficient to cover the manufacture of those cells to an ATMP; tissues and cells procured for 
these purposes are likely to require their own consent process. 
 
All tissue and cell based therapies are required to undergo some type of a process 
optimisation and validation, as well as ongoing quality assessment. There are ethical 
questions related to the use of patient material for these purposes as it is vital to ensure 
that all donations are put to best possible use; but also are used only for the purposes for 
which the donor intended. It is common for manufacturers of ATMPs to seek to use excess 
starting material, or unused products, for internal process development, or long term 
stability testing. The donor should be made aware of this at the point of donation and their 
consent sought. The ethical complexity of this process may be increased where a product is 
being developed by a pharmaceutical company who stand to make a financial gain by 
placing the final ATMP on the market. Any donation of tissues and cells will provide an 
invaluable resource.For ATMPs, patient benefit may lie, for example, in the optimisation of 
the manufacturing process, as well as in the end product. This, however, will not be of direct 
benefit (financial, or otherwise) to the donor and this should be set out as part of the 
consent process.  
 
Testing of donors for provision of starting materials for ATMPs is another area which raises 
ethical considerations that should be covered as part of the consent process. Donors of 
tissues and cells are required to undergo a panel of mandatory serology tests for markers of 
infectious diseases. The donated material itself may also be required to undergo testing for 
certain disease markers, for example as part of product safety testing. The results of these 
tests may carry implications for the health of the donor and their families. How and when 
(or indeed whether) the results of any tests will be communicated to the donor should be 
considered carefully. This will need to be included as part of an informed consent 
procedure. 
 
Guidance on some of these ethical considerations is provided in the HTA Codes of Practice, 
and the government advisory committee SaBTO has produced a review of the Donation of 
Starting Material for Cell-Based Advanced Therapies. As a matter of course, there are some 
general principles which should be adhered to when seeking consent for the donation of 
tissues and cells for ATMP manufacture: 
https://www.hta.gov.uk/guidance-professionals/codes-practice/code-practice-1-consent 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/326823/C
ellular_Therapy.pdf 
 Any donor should be aware that their donation is given freely, as a gift and is without 
financial reward. This is in keeping with European Directive 2004/23/EC of the 
EUTCD which sets out that ' As a matter of principle, tissue and cell application 
programmes should be founded on the philosophy of voluntary and unpaid 
donation, anonymity of both donor and recipient, altruism of the donor and 
solidarity between donor and recipient.' 
 The potential future uses of tissue should be clearly explained; donors should be 
made aware where their tissue could be developed into a commercial product, and 
where this product could potentially be used to treat many recipients.  
 Where applicable, donors should also be made aware of the types of tests the tissue 
may be subjected to and any possible implications for them and their immediate 
family member. 
 
Central to all of the above, is that an informed consent process is crucial to protect 
the safety and well- being of both donor and recipient 
 
 
Conclusions 
 
ATMPs are the ultimate “patient-specific medicines” and will become mainstream 
therapeutic options over the next 5 to 10 years. The range of ATMPs already licensed or 
currently in late phase clinical trials in the US and across the EU is daunting and in 2014 a 
Japanese group reported the first clinical use of an iPS cell derived therapy 
[http://www.dddmag.com/articles/2014/10/japan-starts-world-first-stem-cell-trial-plans-
more] although the trial was subsequently halted due to safety concerns 
[https://www.newscientist.com/article/dn27986/]. It is unlikely that this set back will halt 
the clinical development of iPS therapies.  
The expansion of ATMPs in trials and in routine clinical use will increase the need for 
expertise in cell and tissue procurement substantially and the handling of cryopreserved 
cellular medicines in UK hospitals will increase well beyond conventional HSCT services. 
Meeting these demands will be challenging but UK haematology departments are well 
placed to serve these needs together with hospital-based virology and microbiology 
departments who can provide patient/donor screening services for infectious disease 
markers. Current HSCT units should prepare for the demands this will create by establishing 
an accurate cost model of their service and by reviewing their procurement quality system 
to ensure that it is sufficiently flexible to accommodate the breadth of requests likely to be 
made in the near future and by motivating staff to embrace the challenges ahead. 
 
  
Table 1 – examples of current ATMPs requiring hospital supply of cell/tissue starting 
materials 
 
Product ATMP type Starting material Regulatory status 
Holoclar – limbal 
epithelial cell 
construct 
Combination ATMP: 
Tissue engineered 
product plus 
engineered scaffold 
Limbal biopsy Licensed medicine 
ChondroCelect  Tissue engineered 
product 
Autologous 
chondrocytes 
Licensed medicine 
Mesenchymal 
stromal cells for 
immunomodulation 
Somatic cell therapy Bone marrow 
aspirate 
Investigational or 
unlicensed medicine 
Mesenchymal 
stromal cells for 
tissue regeneration 
Tissue engineered 
product 
Bone marrow 
aspirate 
Investigational or 
unlicensed medicine 
Dendritic cell 
vaccines 
Somatic cell therapy Autologous 
peripheral blood 
monocytes from 
apheresate 
Investigational or 
unlicensed medicine 
TCR-modified T cells Gene therapy 
product (GM 
autologous somatic 
cells) 
Autologous 
apheresate 
Investigational 
medicine 
CAR-T cell Gene therapy 
product (GM 
autologous somatic 
cells) 
Autologous 
apheresate 
Investigational 
medicine 
Activated NK cells Somatic cell therapy Autologous 
apheresate 
Investigational 
medicine 
Regulatory T cells Somatic cell therapy Autologous 
apheresate 
Investigational 
medicine 
Tracheal construct Combination ATMP: 
Tissue engineered 
product plus 
allogeneic human 
scaffold 
Autologous bone 
marrow aspirate 
and 
Tracheal biopsy  
Investigational 
medicine 
iPS cells Gene therapy 
product (GM 
autologous somatic 
cells) 
Skin biopsy Investigational 
medicine 
  
Table 2 – Some considerations in building a business case 
 Licence 
o Cost of use of existing HTA  procurement licence or modifying an existing 
MHRA Blood Establishment licence 
 Is a PPD submission to HTA or a licence amendment to MHRA needed 
for a novel cell / tissue type? 
 Do new staff (e.g. surgeons) need training in HTA / MHRA 
compliance? 
 What paperwork is needed to cover SOP and labelling of new starting 
materials? 
 Are changes needed to your existing database for traceability? 
 Do the new starting materials fall within the “30 day pre-
procurement” concession for stem cells or will they need to be tested 
for infectious disease markers on the day of procurement?  
 Staff 
o Time needed by HTA DI, MHRA responsible person and the departmental 
quality manager to set up each procurement? 
o Additional resources needed in the apheresis unit, the haematology out-
patient clinic and the “stem cell lab”? 
o Who will cost the service and raise invoices to be sent to hospital finance for 
processing? 
o Are there adequate staff in hospital finance to bill users for services provided 
 
 Physical resources 
o Cost of apheresis equipment operation, depreciation, replacement 
o Cost of out-patient appointment for bone marrow aspirate 
o Access to operating theatre time for biopsy retrieval 
o Storage capacity for regulatory compliance paperwork and traceability 
o Is there a process within your Trust to set up and approve contracts for 
provision to academic and commercial customers? 
o Is there a process within your Trust to return part of the income for the 
service to your department as “income” or to offset QIPP? 
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